Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print Created with Sketch. YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Health Study Area: Breast Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Please Log In/Join Now first, and then use this function!

Active, Not Recruiting

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) - CA209-012

Updated: 3 March, 2020   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1

    Phase

  • Gender(s)

  • 18+

    Age Range

  • Active, Not Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Arm A: Nivolumab + Gemcitabine + Cisplatin
Drug: Cisplatin Biological: Nivolumab Drug: Gemcitabine
Experimental: Arm B: Nivolumab + Pemetrexed + Cisplatin
Biological: Nivolumab Drug: Pemetrexed Drug: Cisplatin
Experimental: Arm C: Nivolumab + Paclitaxel + Carboplatin
Biological: Nivolumab Drug: Carboplatin Drug: Paclitaxel
Experimental: Arm D: Nivolumab + Bevacizumab maintenance
Drug: Bevacizumab Biological: Nivolumab
Experimental: Arm E: Nivolumab + Erlotinib
Drug: Erlotinib Biological: Nivolumab
Experimental: Arm F: Nivolumab
Biological: Nivolumab
Experimental: Arm G: Nivolumab + Ipilimumab
Biological: Ipilimumab Biological: Nivolumab
Experimental: Arm H: Nivolumab + Ipilimumab
Biological: Ipilimumab Biological: Nivolumab
Experimental: Arm I: Nivolumab + Ipilimumab
Biological: Ipilimumab Biological: Nivolumab
Experimental: Arm J: Nivolumab + Ipilimumab
Biological: Ipilimumab Biological: Nivolumab
Experimental: Arm K: Nivolumab
Biological: Nivolumab
Experimental: Arm L: Nivolumab
Biological: Nivolumab
Experimental: Arm M: Nivolumab
Biological: Nivolumab
Experimental: Arm N: Nivolumab + Ipilimumab
Biological: Ipilimumab Biological: Nivolumab
Experimental: Arm O: Nivolumab + Ipilimumab
Biological: Ipilimumab Biological: Nivolumab
Experimental: Arm P: Nivolumab + Ipilimumab
Biological: Ipilimumab Biological: Nivolumab
Experimental: Arm Q: Nivolumab + Ipilimumab
Biological: Ipilimumab Biological: Nivolumab
Experimental: Arm R: Nivolumab + Ipilimumab
Biological: Nivolumab Biological: Ipilimumab
Experimental: Arm S: Nivolumab + Ipilimumab
Biological: Ipilimumab Biological: Nivolumab

Key Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Newly diagnosed and confirmed Stage IIIB/IV NSCLC - Previously treated NSCLC with asymptomatic brain metastases (eligible for Arm M) See additional details below - Men and women aged ≥18 years - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 - Subject must be chemotherapy naive (except Arm D, K, L and M). Prior use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is acceptable. For Arms D, K, and L, subjects must be non-progressors within 42 days after completion of first-line treatment with ≥4 cycles of Platinum Doublet chemotherapy with or without Bevacizumab. See below for Arm M - Either a formalin fixed tissue block or a minimum of 10 slides of tumor sample (archived or fresh) must be available for biomarker evaluation (a local pathologist must review for adequacy of sampling) - Life expectancy of at least 3 months - Prior radiotherapy must have been completed at least 2 weeks prior to study entry For Arm M: - No more than 4 brain metastases - Each brain metastases ≤3 cm in size - No evidence of cerebral edema - Subjects must be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroids for ≥10 days prior to initiation of study treatment - At least 1 measurable target brain lesion >0.5 cm and no larger than 3 cm in diameter and/or 2 measurable brain target lesions >0.3 cm - No prior radiation therapy, surgery, or other local therapy for target brain lesions - Must have received at least one prior systemic anticancer therapy for NSCLC Exclusion Criteria: - Subjects with symptomatic brain metastases, spinal cord compression, or intractable back pain due to a compressive or destructive mass - Subjects who require emergent use of systemic steroids, emergent surgery and/or radiotherapy - Any active or history of a known autoimmune disease - Subjects with previous malignancies (except non-melanoma skin cancers, in situ bladder cancer, gastric, or colon cancers or cervical cancers/dysplasia, or breast carcinoma in situ) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period - History of Grade ≥2 neuropathy - Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com